Avidity Biosciences Stock (NASDAQ:RNA)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$41.87

52W Range

$5.15 - $50.78

50D Avg

$44.38

200D Avg

$32.60

Market Cap

$5.25B

Avg Vol (3M)

$1.29M

Beta

0.89

Div Yield

-

RNA Company Profile


Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

253

IPO Date

Jun 12, 2020

Website

RNA Performance


RNA Financial Summary


Dec 23Dec 22Dec 21
Revenue$9.56M$9.22M$9.33M
Operating Income$-235.60M$-178.91M$-118.05M
Net Income$-212.22M$-169.08M$-117.37M
EBITDA$-235.60M$-178.91M$-118.05M
Basic EPS$-2.91$-3.24$-2.83
Diluted EPS$-2.91$-3.24$-2.83

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 14Nov 17, 14 | 5:00 PM
Q2 14Aug 12, 14 | 5:00 PM
Q1 14May 20, 14 | 5:00 PM

Peer Comparison


TickerCompany
PLRXPliant Therapeutics, Inc.
AKROAkero Therapeutics, Inc.
ARVNArvinas, Inc.
CGEMCullinan Oncology, Inc.
RVMDRevolution Medicines, Inc. Warrant
MLYSMineralys Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
STOKStoke Therapeutics, Inc.
CERECerevel Therapeutics Holdings, Inc.
BDTXBlack Diamond Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
BCELAtreca, Inc.
IGMSIGM Biosciences, Inc.
PASGPassage Bio, Inc.
SWTXSpringWorks Therapeutics, Inc.
PTGXProtagonist Therapeutics, Inc.